search
Back to results

Russian Clinical Trial of Mesenchymal Cells in Patients With Septic Shock and Severe Neutropenia

Primary Purpose

Septic Shock, Nonchemotherapy Drug-induced Neutropenia, Neutropenia After Chemotherapy in Oncohematological Patients

Status
Unknown status
Phase
Phase 1
Locations
Russian Federation
Study Type
Interventional
Intervention
Mesenchymal stromal cells
Standard therapy of septic shock
Sponsored by
National Research Center for Hematology, Russia
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Septic Shock focused on measuring Mesenchymal Stromal Cells, Septic Shock, Neutropenia, Procalcitonin, Interleukin-6, Interleukin-10, C-reactive protein, Survival, Organ dysfunction

Eligibility Criteria

17 Years - 75 Years (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

septic shock

≤10 hs after onset of septic shock severe neutropenia(≤ 1 10^9/l) Patients ≥17 years Signed Informed Consent to treatment

Exclusion Criteria:

oncohematological patients with resistance to chemotherapy Unsigned Informed Consent to treatment Age >75 years; Pregnancy

Sites / Locations

  • National Research Center for HematologyRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Experimental

Arm Label

Standard therapy of septic shock

Mesenchymal stromal cells+ standard therapy of septic shock

Arm Description

according to Surviving Sepsis Campaign 2012 Antibiotic therapy Fluid therapy Vasopressors Inotropic therapy Steroids

MSCs intravenous infusion of 1-2 millions/kg/day will be performed not more than 10 hs after onset of septic shock in patients with severe neutropenia(≤ 1x10^9/l). according to Surviving Sepsis Campaign 2012: Antibiotic therapy Fluid therapy Vasopressors Inotropic therapy Steroids

Outcomes

Primary Outcome Measures

mortality

Secondary Outcome Measures

Evaluation of MSC therapy effects on organ dysfunction
Liver: levels of serum total bilirubin, transaminases, lactate dehydrogenase, plasma protrombin level Pancreas: amylase level Renal: number of hemodialysis/ hemodiafiltration, blood urea and creatinine levels Pulmonary: requirement for mechanical ventilation or non-invasive mechanical ventilation, pulmonary function-coefficient, partial oxygen pressure arterial blood level Cardiac: requirement for vasopressors, main parameters obtained from Transpulmonary Thermodilution- Systemic Vascular Resistance Index ( SVRI ), Cardiac Output (CO)
Evaluation of MSC therapy effects on systemic inflammatory parameters
plasma concentration of proinflammatory cytokine IL-6 and the antiinflammatory cytokine IL-10, concentration of procalcitonin, C-reactive protein Fibrinogen level, lactate level , the factor XII-dependent fibrinolytic activity blood routine examination
Evaluation of MSC therapy effects on septic shock reversal
SOFA score

Full Information

First Posted
May 1, 2013
Last Updated
May 8, 2013
Sponsor
National Research Center for Hematology, Russia
search

1. Study Identification

Unique Protocol Identification Number
NCT01849237
Brief Title
Russian Clinical Trial of Mesenchymal Cells in Patients With Septic Shock and Severe Neutropenia
Official Title
Russian Single-center Open Randomized Clinical Trial of the Impact of Mesenchymal Stromal Cells Therapy on Organ Dysfunction and 28-day Mortality in Patients With Septic Shock and Severe Neutropenia.
Study Type
Interventional

2. Study Status

Record Verification Date
May 2013
Overall Recruitment Status
Unknown status
Study Start Date
December 2012 (undefined)
Primary Completion Date
April 2013 (Actual)
Study Completion Date
May 2015 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
National Research Center for Hematology, Russia

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
Septic shock remains a significant clinical problem associated with high rates of mortality among neutropenic patient despite antimicrobial therapy and supportive care. Recently, mesenchymal stromal cells (MSC) have demonstrated remarkable potential effect in sepsis. MSC treatment significantly reduced mortality in septic mice receiving appropriate antimicrobial therapy. MSCs reduced systemic inflammatory cytokine levels in mice, down-regulated of inflammation and inflammation-related genes (such as interleukin-10, interleukin-6). Bacterial clearance was greater in MSC-treated mice. Thus, MSCs have beneficial effects on experimental sepsis and suggest that MSСs-therapy may be an effective adjunctive treatment to reduce sepsis-related mortality. The safety of MSCs is proved by Graft-versus-host disease treatment MSCs in patients after bone marrow transplantation. This study hypothesis is that MSCs reduce organ dysfunction/injury, systemic inflammation and mortality in patients with septic shock and severe neutropenia. The main goal of the study is to evaluate the impact of MSCs therapy on organ dysfunction/injury, systemic inflammation and 28-day mortality in patients with septic shock and severe neutropenia. All patients will be randomized in two groups: control group (standard treatment of septic shock) and MSCs-group (standard treatment of septic shock + MSCs infusion of 1-2 millions/kg/ day).
Detailed Description
All activities related to this human subjects research have been guided by ethical principles and have been reviewed and approved Federalwide Assurance National Ctr for Hematology, FWA00006482. The goal of the trial is to evaluate plasma concentration of proinflammatory cytokine interleukin-6 and the antiinflammatory cytokine interleukin-10, plasma levels of blood creatinine, bilirubin, procalcitonin, C-reactive protein. Then we will evaluate requirement for renal replacement therapy, requirement for mechanical ventilation or non-invasive mechanical ventilation, pulmonary function-coefficient, partial oxygen pressure arterial blood level, electrocardiograms, Kaplan - Meier curve,28-days mortality.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Septic Shock, Nonchemotherapy Drug-induced Neutropenia, Neutropenia After Chemotherapy in Oncohematological Patients, Neutropenia in Patients With Aplastic Anemia
Keywords
Mesenchymal Stromal Cells, Septic Shock, Neutropenia, Procalcitonin, Interleukin-6, Interleukin-10, C-reactive protein, Survival, Organ dysfunction

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1, Phase 2
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
30 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Standard therapy of septic shock
Arm Type
Active Comparator
Arm Description
according to Surviving Sepsis Campaign 2012 Antibiotic therapy Fluid therapy Vasopressors Inotropic therapy Steroids
Arm Title
Mesenchymal stromal cells+ standard therapy of septic shock
Arm Type
Experimental
Arm Description
MSCs intravenous infusion of 1-2 millions/kg/day will be performed not more than 10 hs after onset of septic shock in patients with severe neutropenia(≤ 1x10^9/l). according to Surviving Sepsis Campaign 2012: Antibiotic therapy Fluid therapy Vasopressors Inotropic therapy Steroids
Intervention Type
Genetic
Intervention Name(s)
Mesenchymal stromal cells
Intervention Description
MSCs intravenous infusion of 1-2 millions/kg/day will be performed not more than 10 hs after onset of septic shock in patients with severe neutropenia(≤ 1x10^9/l).
Intervention Type
Drug
Intervention Name(s)
Standard therapy of septic shock
Intervention Description
Antibiotic therapy Fluid therapy Vasopressors Inotropic therapy Steroids
Primary Outcome Measure Information:
Title
mortality
Time Frame
28 days
Secondary Outcome Measure Information:
Title
Evaluation of MSC therapy effects on organ dysfunction
Description
Liver: levels of serum total bilirubin, transaminases, lactate dehydrogenase, plasma protrombin level Pancreas: amylase level Renal: number of hemodialysis/ hemodiafiltration, blood urea and creatinine levels Pulmonary: requirement for mechanical ventilation or non-invasive mechanical ventilation, pulmonary function-coefficient, partial oxygen pressure arterial blood level Cardiac: requirement for vasopressors, main parameters obtained from Transpulmonary Thermodilution- Systemic Vascular Resistance Index ( SVRI ), Cardiac Output (CO)
Time Frame
At Baseline and at day 2,3,7,14,21,28
Title
Evaluation of MSC therapy effects on systemic inflammatory parameters
Description
plasma concentration of proinflammatory cytokine IL-6 and the antiinflammatory cytokine IL-10, concentration of procalcitonin, C-reactive protein Fibrinogen level, lactate level , the factor XII-dependent fibrinolytic activity blood routine examination
Time Frame
At Baseline and at day 2,3,7,14,21,28
Title
Evaluation of MSC therapy effects on septic shock reversal
Description
SOFA score
Time Frame
At Baseline and at day 2,3,7,14,21,28

10. Eligibility

Sex
All
Minimum Age & Unit of Time
17 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: septic shock ≤10 hs after onset of septic shock severe neutropenia(≤ 1 10^9/l) Patients ≥17 years Signed Informed Consent to treatment Exclusion Criteria: oncohematological patients with resistance to chemotherapy Unsigned Informed Consent to treatment Age >75 years; Pregnancy
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Gennady Galstyan, MD PhD
Phone
+7(495)6124859
Email
gengalst@gmail.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Gennady M. Galstyan, MD PhD
Organizational Affiliation
National Research center of Hematology
Official's Role
Principal Investigator
Facility Information:
Facility Name
National Research Center for Hematology
City
Moscow
ZIP/Postal Code
125167
Country
Russian Federation
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Gennady M Galstyan, MD PhD
Phone
+7(495)6124859
Email
gengalst@gmail.com
First Name & Middle Initial & Last Name & Degree
: Gennady M. Galstyan,, MD PhD
First Name & Middle Initial & Last Name & Degree
Elena N. Parovichnikova, MD,PhD
First Name & Middle Initial & Last Name & Degree
Polina M. Makarova, MD
First Name & Middle Initial & Last Name & Degree
Vyacheslav A. Novikov, MD
First Name & Middle Initial & Last Name & Degree
Irina V. Kolosova, MD
First Name & Middle Initial & Last Name & Degree
Stanislav A. Keselman, MD
First Name & Middle Initial & Last Name & Degree
Alexandr Y. Mashkov, MD
First Name & Middle Initial & Last Name & Degree
Anna V. Krechetova, MD, PhD
First Name & Middle Initial & Last Name & Degree
Dmitri Tihomirov, PhD
First Name & Middle Initial & Last Name & Degree
Tatiana A. Garanzha, PhD
First Name & Middle Initial & Last Name & Degree
Larisa A. Kuzmina, MD, PhD

12. IPD Sharing Statement

Citations:
PubMed Identifier
23361625
Citation
Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, Sevransky JE, Sprung CL, Douglas IS, Jaeschke R, Osborn TM, Nunnally ME, Townsend SR, Reinhart K, Kleinpell RM, Angus DC, Deutschman CS, Machado FR, Rubenfeld GD, Webb S, Beale RJ, Vincent JL, Moreno R; Surviving Sepsis Campaign Guidelines Committee including The Pediatric Subgroup. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med. 2013 Feb;39(2):165-228. doi: 10.1007/s00134-012-2769-8. Epub 2013 Jan 30.
Results Reference
background
PubMed Identifier
20558630
Citation
Mei SH, Haitsma JJ, Dos Santos CC, Deng Y, Lai PF, Slutsky AS, Liles WC, Stewart DJ. Mesenchymal stem cells reduce inflammation while enhancing bacterial clearance and improving survival in sepsis. Am J Respir Crit Care Med. 2010 Oct 15;182(8):1047-57. doi: 10.1164/rccm.201001-0010OC. Epub 2010 Jun 17.
Results Reference
background
PubMed Identifier
21231805
Citation
Kebriaei P, Robinson S. Treatment of graft-versus-host-disease with mesenchymal stromal cells. Cytotherapy. 2011 Mar;13(3):262-8. doi: 10.3109/14653249.2010.549688. Epub 2011 Jan 13.
Results Reference
background

Learn more about this trial

Russian Clinical Trial of Mesenchymal Cells in Patients With Septic Shock and Severe Neutropenia

We'll reach out to this number within 24 hrs